跳转到内容

MK-7264

维基百科,自由的百科全书
MK-7264
法律規範狀態
法律規範
  • Investigational New Drug
识别信息
  • 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS号1015787-98-0  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.258.106 編輯維基數據鏈接
化学信息
化学式C14H19N5O4S
摩尔质量353.4
3D模型(JSmol英语JSmol
  • CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
  • InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
  • Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

MK-7264(英語:Gefapixant)是一种磺胺类药物,作为嘌呤P2X受体P2RX3英语P2RX3拮抗剂,可用于治疗慢性咳嗽英语chronic cough[1][2][3]

参考文献

  1. ^ Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulmonary Pharmacology & Therapeutics. June 2019, 56 ( ): 75–78. PMID 30880151. doi:10.1016/j.pupt.2019.03.006. 
  2. ^ Richards D, Gever JR, Ford AP, Fountain SJ. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. British Journal of Pharmacology. July 2019, 176 (13): 2279–2291. PMC 6555852可免费查阅. PMID 30927255. doi:10.1111/bph.14677. 
  3. ^ Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents. December 2019, 29 (12): 943–963. PMID 31726893. doi:10.1080/13543776.2019.1693542.